TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
P/E ratio for TScan Therapeutics, Inc. (TCRX)
P/E ratio as of 2023: -4.29
According to TScan Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.29. At the end of 2022 the company had a P/E ratio of -0.57.
P/E ratio history for TScan Therapeutics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.29 |
| 2022 | -0.57 |
| 2021 | -2.21 |
| 2020 | -10.06 |
| 2019 | -19.98 |